share_log

Redhill Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Mitchell P. Kopin(4.0%),Daniel B. Asher(4.0%), etc.

SEC announcement ·  Feb 2 16:15
Summary by Moomoo AI
On January 25, 2024, RedHill Biopharma Ltd., a biopharmaceutical company, was involved in a significant financial event when Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively referred to as the Reporting Persons) filed a Schedule 13G with the SEC. The filing indicated that each of the Reporting Persons may be deemed to have beneficial ownership of 1,250,000 ordinary shares of RedHill Biopharma, which are represented by American Depositary Shares (ADSs) traded on the New York Stock Exchange under the symbol 'SOS'. This ownership represents approximately 4.0% of the company's class of securities. The filing was made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934 and was completed on February 2, 2024. The Reporting Persons have entered into a Joint Filing Agreement, indicating that they will file jointly in accordance with SEC regulations. The shares in question were related to a Securities Purchase Agreement with RedHill Biopharma, and the Reporting Persons have certified that their acquisition of the shares is not for the purpose of changing or influencing the control of the issuer.
On January 25, 2024, RedHill Biopharma Ltd., a biopharmaceutical company, was involved in a significant financial event when Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively referred to as the Reporting Persons) filed a Schedule 13G with the SEC. The filing indicated that each of the Reporting Persons may be deemed to have beneficial ownership of 1,250,000 ordinary shares of RedHill Biopharma, which are represented by American Depositary Shares (ADSs) traded on the New York Stock Exchange under the symbol 'SOS'. This ownership represents approximately 4.0% of the company's class of securities. The filing was made pursuant to Rule 13d-1(c) of the Securities Exchange Act of 1934 and was completed on February 2, 2024. The Reporting Persons have entered into a Joint Filing Agreement, indicating that they will file jointly in accordance with SEC regulations. The shares in question were related to a Securities Purchase Agreement with RedHill Biopharma, and the Reporting Persons have certified that their acquisition of the shares is not for the purpose of changing or influencing the control of the issuer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more